Can Nanomedicinal Approaches Provide an Edge to the Efficacy of Tyrosine Kinase Inhibitors?

Curr Med Chem. 2023;30(13):1482-1501. doi: 10.2174/0929867329666220618162303.

Abstract

Tyrosine kinase inhibitors (TKIs) are effective drug molecules for the treatment of various cancers. Nanomedicinal interventions and approaches may not only provide carrying capacities for TKIs but also potentially target tumor-specific environments and even cellular compartments. Nano-inspired drug delivery systems may hence enhance the efficacy of the drugs through enhanced tumour-availability resulting in greater efficacy and decreased side effects. A variety of nanosystems have been developed for the delivery of TKIs for the enhanced treatment of cancers, each with their own preparation methods and physicochemical properties. This review will therefore discuss the applicability of nano-interventions towards combination therapies, dose reduction, and greater potential treatment outcomes. The individual nanosystems have been highlighted with emphasis on the developed systems and their efficacy against various cancer cell lines and models.

Keywords: Tyrosine kinase inhibitors; cancer; cell lines; nanomicelles; nanoparticles; nanosystems.

Publication types

  • Review

MeSH terms

  • Humans
  • Neoplasms* / drug therapy
  • Protein Kinase Inhibitors* / chemistry
  • Protein Kinase Inhibitors* / pharmacology
  • Protein Kinase Inhibitors* / therapeutic use
  • Tyrosine Kinase Inhibitors

Substances

  • Protein Kinase Inhibitors
  • Tyrosine Kinase Inhibitors